Get the Stockscreener App
244.65
0.86%
-2.125
Krystal Biotech Inc stock is traded at $244.65, with a volume of 333.35K.
It is down -0.86% in the last 24 hours and up +20.50% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$246.78
Open:
$246.97
24h Volume:
333.35K
Relative Volume:
1.05
Market Cap:
$7.09B
Revenue:
$290.51M
Net Income/Loss:
$89.16M
P/E Ratio:
81.82
EPS:
2.99
Net Cash Flow:
$119.18M
1W Performance:
+4.49%
1M Performance:
+20.50%
6M Performance:
+74.34%
1Y Performance:
+41.09%
1-Day Range:
$242.58
$248.59
1-Week Range:
$227.86
$248.59
52-Week Range:
$122.80
$248.59
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
244.65 | 7.16B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Braidwell LP Purchases 327,067 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech, Inc. $KRYS is Redmile Group LLC's 2nd Largest Position - MarketBeat
Krystal Biotech And 2 Other Growth Stocks Insiders Are Betting On - Yahoo Finance
Krystal Biotech stock hits all-time high at 245.86 USD - Investing.com India
Krystal Biotech stock hits all-time high at 245.86 USD By Investing.com - Investing.com South Africa
First Trust Advisors LP Buys 189,245 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Reaches New 12-Month HighStill a Buy? - MarketBeat
(KRYS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Krystal Biotech, Inc. $KRYS Shares Purchased by Marshall Wace LLP - MarketBeat
Hood River Capital Management LLC Purchases 8,379 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
282,706 Shares in Krystal Biotech, Inc. $KRYS Bought by Norges Bank - MarketBeat
JPMorgan Chase & Co. Sells 9,621 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech Insider Sold Shares Worth $11,007,447, According to a Recent SEC Filing - marketscreener.com
Suma Krishnan Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech (KRYS) president Krishnan sells shares worth $3.3 million By Investing.com - Investing.com South Africa
Krystal Biotech (KRYS) president Krishnan sells shares worth $3.3 million - Investing.com
Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week HighTime to Buy? - MarketBeat
How Krystal Biotech Inc. (4KB) stock trades after earningsJobs Report & High Win Rate Trade Alerts - Newser
Krystal Biotech stock hits all-time high of 221.91 USD By Investing.com - Investing.com Nigeria
Edgestream Partners L.P. Buys Shares of 19,678 Krystal Biotech, Inc. $KRYS - MarketBeat
Why Krystal Biotech Inc. stock could rally in 2025Trade Entry Report & Entry Point Strategy Guides - Newser
How Krystal Biotech Inc. stock reacts to oil pricesWeekly Market Summary & Stock Market Timing Techniques - Newser
Krystal Biotech stock hits all-time high of 221.91 USD - Investing.com
Will Krystal Biotech Inc. stock outperform growth indexes2025 Key Highlights & High Conviction Investment Ideas - Newser
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - The Motley Fool
Is Krystal Biotech Inc. (4KB) stock considered safe havenJuly 2025 Update & AI Driven Price Predictions - Newser
Will Krystal Biotech Inc. (4KB) stock issue positive guidance2025 Fundamental Recap & Daily Technical Forecast Reports - Newser
Will Krystal Biotech Inc. (4KB) stock announce a stock splitJuly 2025 Movers & Comprehensive Market Scan Insights - Newser
Creative Planning Has $1.15 Million Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Is TTK Prestige Limited Undervalued or Overvalued Fair Value ExplainedMarket Liquidity Analysis & Discover Strategies with Fellow Traders - earlytimes.in
Price-Driven Insight from (KRYS) for Rule-Based Strategy - news.stocktradersdaily.com
Universal Beteiligungs und Servicegesellschaft mbH Sells 8,619 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Pharma News: Will Krystal Biotech Inc. stock benefit from AI adoptionWatch List & Stepwise Swing Trade Plans - BỘ NỘI VỤ
Will Krystal Biotech Inc. stock benefit from AI adoptionWeekly Gains Report & Daily Momentum Trading Reports - moha.gov.vn
Krystal Biotech (NASDAQ:KRYS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Krystal Biotech, Inc. (KRYS) Stock Forecasts - Yahoo Finance
Why Krystal Biotech Inc. stock is considered a top pickTreasury Yields & Detailed Earnings Play Alerts - BỘ NỘI VỤ
Rhenman & Partners Asset Management AB Sells 5,000 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech, Inc. to Participate in 8th Annual Evercore Healthcare Conference on December 3, 2025 - Quiver Quantitative
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference - The Manila Times
Krystal Biotech (NASDAQ: KRYS) at 8th Evercore Conference with 10:00 a.m. ET fireside chat - Stock Titan
Handelsbanken Fonder AB Sells 7,500 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Cynosure Group LLC Acquires 2,016 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Krystal Biotech stock hits 52-week high at 213.09 USD By Investing.com - Investing.com Nigeria
Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT - MSN
How Investors Are Reacting To Krystal Biotech (KRYS) Surging Revenue and Global VYJUVEK Expansion - Sahm
Krystal Biotech stock hits 52-week high at 213.09 USD - Investing.com India
Will Krystal Biotech Inc. stock outperform Nasdaq indexWeekly Trading Summary & Stock Portfolio Risk Control - newser.com
Krystal Biotech (KRYS) Secures FDA Orphan Status for Hailey-Hail - GuruFocus
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):